Patents by Inventor Enzo Martegani

Enzo Martegani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterodimeric peptide compounds displaying NGF activity and their use to treat neurodegenerative disorders
    Patent number: 8461110
    Abstract: Peptides having a structure characterized by the presence of two loops constrained in cyclic structure by the presence of covalent bonds between amino acid side chains, the amino acid sequences of the first and the second loop being substantially homologues to that of loop 1 (residues 29-38) and of loop 4 (residues 92-97) of NGF, respectively, displaying nerve growth factor (NGF) agonist or partial agonist activity.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: June 11, 2013
    Assignee: Blueprint Pharma S.R.L.
    Inventors: Luigi Vitagliano, Laura Zaccaro, Giancarlo Morelli, Enzo Martegani
  • Heterodimeric Peptide Compounds Displaying Ngf Activity and Their Use to Treat Neurodegenerative Disorders
    Publication number: 20090318335
    Abstract: Peptides having a structure characterized by the presence of two loops constrained in cyclic structure by the presence of covalent bonds between amino acid side chains, the amino acid sequences of the first and the second loop being substantially homologues to that of loop 1 (residues 29-38) and of loop 4 (residues 92-97) of NGF, respectively, displaying nerve growth factor (NGF) agonist or partial agonist activity.
    Type: Application
    Filed: June 9, 2006
    Publication date: December 24, 2009
    Inventors: Luigi Vitagliano, Laura Zaccaro, Giancarlo Morelli, Enzo Martegani
  • Method for the Production of Biologically Active Rhngf
    Publication number: 20080214464
    Abstract: The present invention relates to a new rhNGF (recombinant human Nerve Growth Factor) where said rhNGF is characterized by the fact that it presents an in vitro and in vivo activity comparable to that of the native murine NGF. The present invention also relates to the process for the production of said rhNGF, said process adapted for production on middle and large scale, and the modified cells capable of producing said rhNGF.
    Type: Application
    Filed: September 23, 2005
    Publication date: September 4, 2008
    Applicant: BLUEPRINT BIOTECH Srl
    Inventors: Lilia Filippa Anna Alberghina, Anna Maria Colangelo, Enzo Martegani